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DAPT Study: Continuation of Dual Antiplatelet 
Therapy After PCI in Patients With and Without 
Acute Myocardial Infarction (MI) Beyond 1 Year 
Reduced Ischemic Events, but Increased Bleeding 
Compared With Treatment With Aspirin Alone  
Among 11,648 randomized patients (9,961 treated 
with DES, 1,687 with BMS), 30.7% presenting with MI, 
between 12 and 30 months, continued thienopyridine 
reduced stent thrombosis compared with placebo in 
patients with and without MI at presentation (MI group, 
0.5% vs 1.9%, p< 0.001; no MI group, 0.4% vs. 1.1%, p< 
0.001). The reduction in major adverse cardiovascular 
and cerebrovascular events (MACCE) for continued 
thienopyridine was greater for patients with MI (3.9% vs 
6.8%; p< 0.001 for MI; 4.4% vs 5.3%; p= 0.08 for no 
MI). In both groups, continued thienopyridine reduced 
MI (2.2% vs 5.2%, p< 0.001 for MI; 2.1% vs 3.5%, p< 
0.001 for no MI) but increased bleeding (1.9% vs 0.8%, 
p= 0.005 for MI; 2.6% vs 1.7%, p= 0.007 for no MI). The 
authors concluded that extended dual antiplatelet therapy 
reduced the risk of stent thrombosis and MI in patients 
with and without MI, but increased bleeding (Yeh RW et 
al, J Am Coll Cardiol 2015;65:2211-2221).   
Metaanalysis: Dual Antiplatelet Therapy (DAPT) is 
Associated With Protection Against Stent Thrombosis 
but Increases Risk of Bleeding in Patients With Drug 
Eluting Stents (DES) / Benefit of Extended DAPT for 
Patients With First-Generation DES, but not for 
Second-Generation DES  
Metaanalysis of 10 randomized controlled trials (N = 
32,135) indicated that compared to longer duration DAPT 
(L-DAPT; mean exposure time 20.3 months for second-
generation DES and 28 months for first-generation DES), 
shorter duration DAPT (S-DAPT; mean exposure time 
7.8 months for second-generation DES and 10.9 months 
for first-generation DES) had an overall higher rate of 
stent thrombosis (odds ratio - OR: 1.71; p = 0.001). The 
effect of S-DAPT on stent thrombosis was attenuated 
with the use of second-generation DES (OR: 1.54) 
compared with first-generation DES (OR: 3.94; p for 
interaction = 0.008). S-DAPT had an overall significantly 
lower risk of bleeding (OR: 0.63; p < 0.001). Finally, a 
numerically lower all-cause mortality rate was observed 
with S-DAPT (OR: 0.87; p = 0.073). The authors conclu-
ded that S-DAPT had overall lower rates of bleeding, yet 
higher rates of stent thrombosis compared with L-DAPT; 
the latter effect was significantly attenuated with the use 
of second-generation DES. All-cause mortality was 
higher (not statistically) with L-DAPT (Giustino G et al, J 
Am Coll Cardiol 2015;65: 1298-1310).    
ISAR-TRIPLE Trial: Antithrombotic Therapy in 
Patients with Indications for Oral Anticoagulation 
Undergoing Implantation of DES is Problematic / A 
Shorter (6-week) Course of Triple Therapy was not 
Superior to a Longer (6-Month) Course for Major 
Bleeding and Ischemic Events  
A total of 614 patients receiving concomitant aspirin 
and oral anticoagulant (OAC) were randomized to either 
6-week (n=307) or 6-month clopidogrel therapy (n= 307). 
The primary endpoint (composite of death, myocardial 
infarction - MI, stent thrombosis, stroke, or TIMI major 
bleeding at 9 months) occurred in 30 patients (9.8%) in 
the 6-week group compared with 27 patients (8.8%) in 
the 6-month group (hazard ratio - HR: 1.14; p = 0.63). 
There were no significant differences for the secondary 
combined ischemic endpoint of cardiac death, MI, stent 
thrombosis, and ischemic stroke or the secondary 
bleeding endpoint of TIMI major bleeding. The authors 
concluded that 6 weeks of triple therapy was not superior 
to 6 months with respect to net clinical outcomes (Fiedler 
KA et al, J Am Coll Cardiol 2015; 1819-1629).   
SYMPLICITY-3: 6-Month Negative Results of Renal 
Denervation Remain Negative at 12 Months  
The SYMPLICITY HTN-3 trial confirmed safety but 
not efficacy of renal denervation for treatment-resistant 
hypertension at 6 months. The 12-month results, available 
for 319 of 361 denervation subjects and 48 of 101 non-
crossover subjects, showed that in denervation subjects, 
the office systolic BP (SBP) change was greater than that 
observed at 6 months (−15.5 ± 24.1 mmHg vs −18.9 ± 
25.4 mmHg, respectively; p= 0.025), but the 24-h SBP 
change was not significantly different at 12 months 
(p=0.229). The non-crossover group office SBP 
decreased by −32.9 ± 28.1 mmHg at 6 months, but this 
response was reduced to −21.4 ± 19.9 mmHg (p= 0.01) at 
12 months, increasing to 11.5 ± 29.8 mmHg. The authors 
concluded that there was no further reduction in office or 
ambulatory blood pressure after 1-year follow-up, while 
there was loss of blood pressure reduction in the non-
crossover group, probably reflecting decreased 
medication adherence (Bakris G et al, J Am Coll Cardiol 
2015;65:1314-1321).  
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Low-Risk AF Patients, i.e., CHA2DS2-VASc= 0 (Male), 
= 1 (Female) Have a Low Risk for Stroke, Cerebral 
and Major Bleeding / With 1 Additional Stroke Risk 
Factor, i.e., CHA2DS2-VASc = 1 (Male), = 2 (Female), 
there is a Significant Increase in Event Rates, 
Including Mortality, if Non-anticoagulated  
According with a Danish study of 39,400 patients 
discharged with diagnosis of nonvalvular atrial 
fibrillation (AF) with 0 or 1 CHA2DS2-VASc risk factor, 
23,572 were not treated, 5,353 were on aspirin, and 
10,475 received warfarin. Stroke event rates for untreated 
low-risk patients (CHA2DS2-VASc= 0 [male], 1 
[female]) were 0.49 per 100 person-years at 1 year and 
0.47 per 100 person-years at full follow-up. Bleeding 
event rates among untreated low-risk patients were 1.08 
per 100 person-years at 1 year and 0.97 at full follow-up. 
The presence of 1 additional stroke risk factor, i.e. 
CHA2DS2-VASc = 1 (male), = 2 (female) among 
untreated patients increased the stroke rate at 1 year to 
1.55 per 100 person-years, representing a 3-fold increase. 
At 1-year, bleeding increased 2.35-fold, and death 
increased 3.12-fold. The authors concluded that low-risk 
patients, i.e. CHA2DS2-VASc = 0 (male), 1 (female) 
have a truly low risk for stroke and bleeding. With 1 
additional stroke risk factor, i.e. CHA2DS2-VASc = 1 
(male), = 2 (female), there was a significant increase in 
event rates (particularly mortality) if non-anticoagulated 
(Lip G et al, J Am Coll Cardiol 2015;65: 1385-1394).   
EFFORTLESS Trial: The Subcutaneous ICD (S-ICD) 
Showed High Shock Efficacy for Ventricular 
Arrhythmias and a Decreasing Incidence of 
Inappropriate Shocks With Acceptable Complication 
Rate and Low Mortality Rate Extended at 2 Years 
Among 882 patients who received a S-ICD followed 
for a mean of 2 years, arrhythmia events (n= 111) were 
treated in 59 patients; 100 (90.1%) events were 
terminated with 1 shock, and 109 events (98.2%) within 
the 5 available shocks. The estimated 3-year 
inappropriate shock rate was 13.1%, and all-cause 
mortality 4.7%, with 26 deaths (2.9%). Device-related 
complications occurred in 11.1%; there were no electrode 
failures, and no S-ICD–related endocarditis or 
bacteremia. Three devices (0.3%) were replaced for right 
ventricular pacing. The 6-month complication rate 
decreased by quartile of enrollment (Q1: 8.9%; Q4: 
5.5%), and there was a trend toward a reduction in 
inappropriate shocks (Q1: 6.9% Q4: 4.5%). The authors 
concluded that the S-ICD demonstrated high efficacy; 
rates of complications and inappropriate shocks were 
reduced consistently with strategic programming and as 
operator experience increased (Burke MC et al, J Am Coll 
Cardiol 2015;65:1605-1615).  
Leadless Cardiac Pacemakers Exhibit Stable Elec-
trical Performance Without Device-Related Adverse 
Events at 1 Year in a Small Cohort of 31 Patients  
Follow-up of 31 of 33 patients (aged 76 ± 8 years; 
65% male) from the LEADLESS trial who received a 
leadless VVI pacemaker indicated that between 3 and 12 
months of follow-up, there were no pacemaker-related 
adverse events reported. The pacing performance 
remained stable, with adequate rate response observed in 
all (61%) patients in whom it was activated. The authors 
concluded that the leadless pacemaker demonstrates very 
stable performance and good safety results at 1 year 
(Knops RE et al, J Am Coll Cardiol 2015;1497-1504 ).   
LEGACY Study: Sustained Weight Loss Reduces AF 
Burden & Maintains Sinus Rhythm Probably Related 
to Favorable Changes in Cardiometabolic Risk Factor 
Profile, Inflammatory State, and Cardiac Remodeling 
Among 3 groups based on weight loss achieved 
(≥10%, 3-9%, and <3%).) of 355 obese (body mass index 
≥27 kg/m2) patients with atrial fibrillation (AF), offered 
weight management, AF burden and symptom severity 
decreased more in group 1 compared with groups 2 and 3 
(p< 0.001 for all). Arrhythmia-free survival regardless of 
rhythm or rate control strategies was also greatest in 
group 1 (p< 0.001 for both). Weight loss and weight 
fluctuation were independent predictors of outcomes (p< 
0.001). Weight loss ≥10% resulted in a 6-fold (p< 0.001) 
greater probability of arrhythmia-free survival. Weight 
fluctuation >5% partially offset this benefit, with a 2-fold 
(p = 0.02) increased risk of arrhythmia recurrence. The 
authors concluded that long-term sustained weight loss is 
associated with significant reduction of AF burden and 
maintenance of sinus rhythm (Pathak RK et al, J Am Coll 
Cardiol 2015;65:2159-2169).    
German Aortic Valve Registry (GARY, 2011-2013): 
Incidence of Severe Vital Complications (SVCs) and 
Technical Procedural Complications (TCOs) 
Decreased Significantly From Year to Year, but 
Remained at ~4% With no Changes in Need for 
Sternotomy (~1.2%) and In-Hospital Death (~5%)  
Among 15,964 transcatheter aortic valve replacement 
(TAVR) procedures (mean age 81±6 years, 54% women, 
median logistic Euroscore I 18.3), in-hospital mortality 
was 5.2%, whereas SVCs occurred in 5%. Independent 
predictors for SVCs were female gender, pre-operative 
NYHA class IV, ejection fraction <30%, pre-operative IV 
inotropes, arterial vascular disease, and higher degree of 
calcifications. TCOs occurred in 4.7% and decreased 
significantly from 2011 to 2013. An emergency 
sternotomy was performed in 1.3% of the patients. The 
authors concluded that TAVR had good outcomes and a 
regression in complications. Survival of patients who 
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experienced SVCs or who required sternotomy was ~60% 
(Walther T et al, J Am Coll Cardiol 2015;65:2173-2180).   
Nordic Aortic Valve Intervention (NOTION) Trial: 
Comparing Transcatheter (TAVR) With Surgical 
Aortic Valve Replacement (SAVR) in an All-Comers 
Patient Cohort, no Significant Differences were Found 
Regarding the Primary Outcome (Death, Stroke, or 
MI) or the Exploratory Outcomes of Cardiovascular 
Mortality or Prosthesis Reintervention After 1 Year 
Among 280 (mean age 79; 82% considered low-risk) 
patients randomized to TAVR or SAVR, no significant 
difference in the primary endpoint (death, stroke, or MI) 
was found (13.1% vs 16.3%). No difference in the rate of 
cardiovascular death or prosthesis reintervention was 
found. TAVR led to more pacemakers due to conduction 
abnormalities, larger improvement in effective orifice 
area, more total aortic valve regurgitation, and higher 
NYHA functional class at 1 year. SAVR patients had 
more major or life-threatening bleeding, cardiogenic 
shock, acute kidney injury, and new-onset or worsening 
atrial fibrillation at 30 days. The authors concluded that 
no significant difference between TAVR and SAVR was 
found for the composite rate of death from any cause, 
stroke, or MI after 1 year (Thyregod HG et al, J Am Coll 
Cardiol 2015;65:2184-2194).  
PRECOMBAT Study: No Difference Over 5 Years in 
MACCE Between PCI With Sirolimus Eluting Stents 
and CABG for Patients Treated for Unprotected Left 
Main Coronary Artery Stenosis 
Among 600 patients with unprotected left main 
stenosis undergoing PCI with a sirolimus-eluting stent 
(300) or CABG (300), at 5 years, the primary endpoint 
(major adverse cardiovascular events - MACCE: a 
composite of death, MI, stroke, or ischemia-driven target 
vessel revascularization) occurred in 52 patients in the 
PCI and 42 patients in the CABG group (event rates of 
17.5% & 14.3%, respectively; hazard ratio - HR: 1.27; 
p=0.26). The 2 groups did not differ significantly in terms 
of death from any cause, MI, or stroke as well as their 
composite (8.4% & 9.6%; HR, 0.89; p= 0.66). Ischemia-
driven target vessel revascularization occurred more 
frequently in the PCI group than in the CABG group 
(11.4% and 5.5%, respectively; HR: 2.11; p = 0.012) 
(Ahn JM et al, J Am Coll Cardiol 2015;65:2198-2206).   
Therapeutic Manipulation of miRNA to Reduce In-
Stent Restenosis / in Pig, Mouse, & in Vitro Models, 
miR-21 Promotes Vascular Inflammation & Remode-
ling After Stenting and May be a Therapeutic Target 
to Enhance Wound Healing After Vascular Injury 
A subset of inflammatory miRNAs was documented 
which was activated after stenting in pigs, including the 
miR-21 stem loop miRNAs. Genetic ablation of the miR-
21 stem loop attenuated neointimal formation in mice 
post-stenting. This occurred via enhanced levels of anti-
inflammatory M2 macrophages coupled with an impaired 
sensitivity of smooth muscle cells to respond to vascular 
activation. In conclusion, miR-21 plays a prominent role 
in promoting vascular inflammation and remodeling after 
stent injury and may be a therapeutic target to enhance 
wound healing after vascular injury (McDonald RA et al, 
J Am Coll Cardiol 2015;65:2314-2327).   
Meta-Analysis: Fewer Hemorrhagic Strokes, 
Cardiovascular Death, and Nonprocedural Bleeding, 
Similar All-cause Strokes or Systemic Embolism, but 
More Ischemic Strokes With LAA Closure Compared 
With Warfarin 
A meta-analysis of PROTECT AF and PREVAIL 
trials, and their registries indicated that at a mean follow-
up of 2.69 years, patients receiving left atrial appendage 
closure (LAAC) with the Watchman device had fewer 
hemorrhagic strokes (hazard ratio - HR: 0.22; p= 0.004), 
cardiovascular/ unexplained death (HR: 0.48; p= 0.006), 
and nonprocedural bleeding (HR: 0.51; p= 0.006) 
compared with warfarin. All-cause stroke or systemic 
embolism was similar, but there were more ischemic 
strokes in the device group (HR: 1.95 and 0.22, 
respectively; p= 0.05 / 0.004) (Holmes DR et al, J Am 
Coll Cardiol 2015;65:2614-2623).   
Safe Full-Body MRI in Patients With a Specifically 
Designed Implantable Cardioverter-Defibrillator 
(ICD) System: First-in-Human Randomized Study  
A total of 275 patients (76% male, age 60.4 ± 13.8 
years) received an MRI-safe single- or dual-chamber ICD 
(Evera MRI ICD, Medtronic) designed for full-body 
imaging. Patients were randomly assigned 2:1 to undergo 
full-body MRI (MRI group, n=175; 1.5-T) or to undergo 
a 1-h waiting period without MRI (control group, n=88) 9 
to 12 weeks after implant. A subset of MRI patients 
underwent ventricular fibrillation induction testing post-
MRI to characterize defibrillation function. The safety 
endpoint was met with 100% freedom from the composite 
endpoint (MRI-related events: occurrence of sustained 
ventricular tachyarrhythmia during MRI exposure, 
complication within 30 days related to the MRI, or loss of 
capture within 30 days of MRI; p< 0.0001). A total of 34 
ventricular tachyarrhythmia/ventricular fibrillation 
episodes (20 induced; 14 spontaneous) occurred in 24 
patients post-MRI, with no observed effect on sensing, 
detection, or treatment. The authors concluded that this 
ICD system designed for full-body MRI at 1.5-T is safe 
and the MRI scan does not adversely affect electrical 
performance or efficacy (Gold MR et al, J Am Coll 
Cardiol 2015;65:2581-2588).  
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Review & Metaanalysis: Strong Evidence of the Safety 
of Remote Monitoring (RM) of ICDs, with the 
Suggestion of a Potential Mortality Benefit  
Data from 9 randomized controlled trials (RCTs) 
reporting clinical outcomes of 6,469 ICD patients who 
did (n=6,469) or did not undergo RM (n=3,496), 
indicated clinical outcomes of RM comparable with 
office follow-up for all-cause mortality (odds ratio - OR: 
0.83; p= 0.285), cardiovascular mortality (OR: 0.66; p= 
0.103), and hospitalization (OR: 0.83; p= 0.196). 
However, a reduction in all-cause mortality was noted in 
the 3 trials using home monitoring (OR: 0.65; p= 0.021) 
with daily verification of transmission. Also the odds of 
inappropriate shock were reduced in RM patients (OR: 
0.55; p= 0.002) (Parthiban N et al, J Am Coll Cardiol 
2015;65:2591-2600).   
CARDIA Study: Cumulative Blood Pressure (BP) 
Exposure in Early Adulthood Leads to Cardiac 
Dysfunction in Middle Age  
 At the year 25 examination of 2,479 participants, 
cumulative BP measures were not related to LV ejection 
fraction; however, high cumulative exposure to systolic 
blood pressure (SBP) and diastolic blood pressure (DBP) 
were associated with lower longitudinal strain rate (both 
p< 0.001). For diastolic function, higher cumulative 
exposures to SBP and DBP were associated with low 
early diastolic longitudinal peak strain rate (Kishi S et al, 
J Am Coll Cardiol 2015;65:2679-2687).   
Digoxin Use in Registry Patients with AF had a 
Neutral Association with Outcomes Under Most 
Circumstances 
Among 9,619 patients with atrial fibrillation (AF) and 
serial follow-up every 6 months for up to 3 years, 2,267 
(23.6%) received digoxin at enrollment, 681 (7.1%) 
during follow-up, and 6,671 (69.4%) never took digoxin. 
Digoxin use at registry enrollment was not associated 
with subsequent onset of symptoms, hospitalization, or 
mortality. Incident digoxin use during follow-up was not 
associated with subsequent death in patients with heart 
failure, but was associated with subsequent death in those 
without heart failure (hazard ratio-HR: 1.99) (Allen LA et 
al, J Am Coll Cardiol 2015;65:2691-2698).  
 
ROCKET AF: Retrospective Analysis Indicated that 
Digoxin Treatment was Associated With a Significant 
Increase in All-Cause Mortality, Vascular Death, and 
Sudden Death in Patients With Atrial Fibrillation 
Retrospective analysis of 5,239 (37%) out of 14,171 
randomly assigned patients, receiving digoxin, more 
likely female (42% vs 38%) and having a history of heart 
failure (73% vs 56%), diabetes (43% vs 38%), and 
persistent atrial fibrillation (AF) (88% vs 77%; 
p<0.0001), showed that digoxin was associated with 
increased all-cause mortality (5.41 vs 4.30 events per 100 
patients-years; hazard ratio - HR 1.17; p=0.0093), 
vascular death (3.55 vs 2.69 per 100 patient-years; HR 
1.19; p=0·0201), and sudden death (1.68 vs 1.12 events 
per 100 patient-years; HR 1.36; p=0.0076). These data 
indicate that a randomized trial of digoxin in treatment of 
AF patients with and without heart failure is needed 
(Washam JB et al, Lancet 2015; 385(9985):2363–2370).   
TTM Trial: Comparable Cognitive Function in 
Survivors of Out-of-Hospital Cardiac Arrest After 
Target Temperature Management at 33°C vs 36°C 
Among 652 cardiac arrest survivors randomized to 
temperature control at 33°C or 36°C, survival until 180 
days after the arrest was 52% (33°C, n=178/328; 36°C, 
n=164/324). A total of 287 cardiac arrest survivors (33°C, 
n=148/36°C, n=139) were assessed with tests for 
memory, executive functions, and attention/mental speed 
and compared with a control group (n=119). Half of the 
cardiac arrest survivors had cognitive impairment, which 
was mostly mild. Cognitive outcome did not differ 
(P>0.30) between the 2 temperature groups (33°C/36°C). 
Compared with control subjects, attention/mental speed 
was more affected among cardiac arrest patients, but 
results for memory and executive functioning were 
similar (Lilja G et al, Circulation 2015;131: 1340-1349).  
Some Chronic Heart Failure Patients Without Atrial 
Fibrillation (AF) are at High Risk for Stroke 
Pooled data from 2 heart failure trials, the CORONA 
and the GISSI-HF, comprising 9585 patients, of whom 
6054 did not have AF, indicated stroke occurrence in 165 
patients (4.7%) with AF and in 206 patients (3.4%) 
without AF. Independent predictors of stroke in patients 
without AF included age (hazard ratio-HR, 1.34 per 10 
years), New York Heart Association class (HR 1.60, class 
III/IV vs II), insulin-treated diabetes mellitus (1.87), body 
mass index (0.74, per 5 kg/m2 up to 30), and previous 
stroke (1.81). N-terminal pro B-type natriuretic peptide 
(n=2632 patients) was also an independent predictor of 
stroke (HR, 1.31) when added to this model (Abdul-
Rahim AH et at, Circulation 2015;131:1486-1494).   
ARIC Study: Atrial Fibrillation (AF) Confers 
Increased Risk of Non–ST-Segment–Elevation 
Myocardial Infarction (NSTEMI) 
The association between AF and incident MI was 
examined in 14 462 participants (mean age, 54 years; 
56% women; 26% blacks) who were free of coronary 
heart disease at baseline. Over a median follow-up of 
21.6 years, 1374 MI events occurred (829 NSTEMIs, 249 
STEMIs, 296 unclassifiable MIs). AF (n=1545) was 
associated with a 63% increased risk of MI (hazard ratio, 
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1.63), specifically NSTEMI (hazard ratio, 1.80) but not 
STEMI (hazard ratio, 0.49; P for hazard ratio 
comparison=0.004). The association between AF and MI, 
total and NSTEMI, was stronger in women than in men 
(Soliman EZ et al, Circulation 2015;131: 1843-1850).  
Most Cardiotoxicity of Anthracycline Occurs Within 
the First Year and is Associated With Anthracycline 
Dose and LVEF at the End of Treatment / Early 
Detection and Prompt Therapy Appear Crucial for 
Recovery  
In a cohort of 2625 patients receiving anthracycline-
containing therapy, cardiotoxicity occurred in 9% 
(n=226) at a median time of 3.5 months after the end of 
chemotherapy, and in 98% of cases (n=221), it occurred 
within the first year. Twenty-five (11%) patients had full 
and 160 (71%) partial recovery. End-chemotherapy 
LVEF (hazard ratio - HR, 1.37; for each percent unit 
decrement) and cumulative doxorubicin dose (HR, 1.09; 
for each 50 mg/m2 increment) were independent 
correlates of cardiotoxicity (Cardinale D et al, Circulation 
2015;131: 1981-1988).   
Oxygen Commonly Administered to Patients With 
STEMI May Increase Myocardial Injury Due to 
Coronary Vasoconstriction and Heightened Oxidative 
Stress 
In a multicenter, prospective, randomized, controlled 
trial comparing oxygen (8 L/min) with no supplemental 
oxygen in 441 patients with ST-elevation–myocardial 
infarction (STEMI), mean peak troponin was similar in 
the oxygen and no oxygen groups (57.4 vs 48.0 μg/L; 
ratio, 1.20; P=0.18). However, there was a significant 
increase in peak creatine kinase (1948 vs 1543 U/L; 
means ratio, 1.27; P=0.01), in the rate of recurrent MI 
(5.5% vs 0.9%; P=0.006) and in frequency of cardiac 
arrhythmia (40.4% vs 31.4%; P=0.05) in the oxygen 
group. At 6 months, the oxygen group had an increase in 
MI size on cardiac magnetic resonance (n=139; 20.3 vs 
13.1 g; P=0.04). The authors concluded that supplemental 
oxygen therapy in patients with STEMI but without 
hypoxia may increase early myocardial injury and cause 
larger infarct size assessed at 6 months (Stub D et al, 
Circulation 2015;131: 2143-2150).  
STROKESTOP Study: Mass Screening in a 75- to 76-
Year-Old Population Identifies a Significant 
Proportion (3%) of Participants With Untreated 
Atrial Fibrillation (AF) 
Systematic screening using intermittent ECG 
recordings over 2 weeks among 7,173 75- to 76-year-old 
individuals without a previous diagnosis of AF uncovered 
218 (3%) to have previously unknown AF, and of these, 
AF was found in 37 (0.5% of the screened population) on 
their first ECG. The use of intermittent ECGs increased 
new AF detection 4-fold. AF was previously diagnosed in 
9.3% (n=666). Total AF prevalence in the screened 
population was 12.3%. Of participants with known AF, 
149 (2.1%) had no oral anticoagulant (OAC) treatment. In 
total, 5.1% of the screened population had untreated AF; 
screening resulted in initiation of OAC treatment in 3.7%, 
with >90% of the participants with previously 
undiagnosed AF accepting initiation of OAC treatment 
(Svennberg E et al, Circulation 2015;131: 2176-2184).  
In Symptomatic Patients With Suspected Coronary 
Artery Disease (CAD), a Strategy of Initial Computed 
Tomography Coronary Angiography (CTA), 
Compared With Functional Testing, did not Improve 
Clinical Outcomes Over a Median of 2 Years 
A total of 10,003 patients (aged 61+8) with symptoms 
suggestive of CAD (88% chest pain or dyspnea on 
exertion), and pretest likelihood of CAD 53±21%, were 
randomized to a strategy of computed tomographic 
coronary angiography (CTA) or to functional testing 
(exercise electrocardiography, nuclear stress testing, or 
stress echocardiography). Over median follow-up of ~2 
years, a primary end-point event (death, myocardial 
infarction, hospitalization for unstable angina, or major 
procedural complication) occurred in 164 of 4996 
patients in the CTA group (3.3%) and in 151 of 5007 
(3%) in the functional-testing group (P=NS). CTA was 
associated with fewer catheterizations showing no 
obstructive CAD (3.4% vs. 4.3%, P=0.02), although more 
patients in the CTA group underwent catheterization 
within 90 days after randomization (12% vs 8%). Median 
cumulative radiation exposure was lower in the CTA 
group (10 vs 11 mSv), but 32.6% of the patients in the 
functional-testing group had no exposure, thus overall 
exposure was higher in the CTA group (mean, 12 mSv vs 
10 mSv; P<0.001) (Douglas PS et al, N Engl J Med 2015; 
372:1291-1300).   
TOTAL Trial: In Patients With STEMI Undergoing 
Primary PCI, Routine Manual Thrombectomy did not 
Reduce Cardiovascular Death, Recurrent MI, 
Cardiogenic Shock, or NYHA Class IV Heart Failure 
at 6 Months, But Conferred More Strokes at 1 Month 
Among 10,732 patients with STEMI undergoing 
primary PCI randomized to manual thrombectomy vs PCI 
alone, the primary outcome (death from cardiovascular 
causes, recurrent MI, cardiogenic shock, or NYHA class 
IV heart failure) occurred in 347 of 5033 patients (6.9%) 
in the thrombectomy group vs 351 of 5030 patients (7%) 
in the PCI-alone group (P=NS). The rates of 
cardiovascular death (3.1% vs 3.5%) and primary 
outcome plus stent thrombosis or target-vessel 
revascularization (9.9% vs 9.8%) were also similar. 
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Stroke within 30 days occurred in 33 patients (0.7%) in 
the thrombectomy group vs 16 patients (0.3%) in the PCI-
alone group (hazard ratio, 2.06; P=0.02) (Jolly SS et al, N 
Engl J Med 2015; 372:1389-1398).  
 
Added Atrial Fibrillation (AF) Ablation to Mitral-
Valve Surgery Led to Higher Rate of Freedom from 
AF at 1 Year Among Patients With Persistent or 
Long-Standing Persistent AF, but Increased the Risk 
for a Permanent Pacemaker  
A total of 260 patients with persistent or long-standing 
persistent AF who required mitral-valve surgery were 
randomized to undergo either concomitant surgical 
ablation (ablation group), either via pulmonary vein 
isolation or biatrial maze procedure, or no ablation 
(control group), all with closure of the left atrial 
appendage. More patients in the ablation group than in 
the control group were free from AF at both 6 and 12 
months (63% vs 29%, P<0.001). There was no significant 
difference between patients who underwent pulmonary-
vein isolation and those who underwent biatrial maze 
procedure (61% and 66%). One-year mortality was 6.8% 
in the ablation group and 8.7% in the control group 
(P=NS). Ablation was associated with more implantations 
of a permanent pacemaker (21.5 vs 8.1 per 100 patient-
years, P=0.01) (Gillinov AM et al, N Engl J Med 2015; 
372:1399-1409).  
 
OSLER Studies: Over 1 Year, Use of Evolocumab 
Plus Standard Therapy, Compared With Standard 
Therapy Alone, Reduced LDL Cholesterol and 
Cardiovascular Events  
A total of 4465 patients who had completed 1 of 12 
phase 2 or 3 studies (“parent trials”) of evolocumab, were 
randomly assigned in a 2:1 ratio to receive either 
evolocumab (140 mg every 2 weeks or 420 mg monthly) 
plus standard therapy or standard therapy alone. Over 
11.1 months, evolocumab reduced LDL cholesterol by 
61%, from a median of 120 to 48 mg/dl (P<0.001). Most 
adverse events occurred with similar frequency in the two 
groups, although neurocognitive events were reported 
more frequently in the evolocumab group. The rate of 
cardiovascular events at 1 year was reduced from 2.18% 
in the standard-therapy group to 0.95% in the 
evolocumab group (hazard ratio, 0.47; P=0.003) 
(Sabatine MS et al, N Engl J Med 2015; 372:1500-1509).  
 
ODYSSEY LONG TERM Trial: Over 78 Weeks, 
Alirocumab, When Added to Statin Therapy at 
Maximum Tolerated Dose, Significantly Reduced 
LDL Cholesterol, with Evidence of Reduction in 
Cardiovascular Events With Alirocumab 
A total of 2341 patients at risk for cardiovascular 
events with LDL>70 mg/dl (1.8 mmol/L) receiving 
treatment with statins at the maximum tolerated dose, 
with or without other lipid-lowering therapy, were 
randomly assigned in a 2:1 ratio to receive alirocumab 
(150 mg) or placebo as a 1-ml subcutaneous injection 
every 2 weeks for 78 weeks. At week 24 and through 78 
weeks, the difference between the alirocumab and 
placebo groups in the mean percentage change from 
baseline in LDL cholesterol level was −62% points 
(P<0.001). The alirocumab group had higher rates of 
injection-site reactions (5.9% vs 4.2%), myalgia (5.4% vs 
2.9%), neurocognitive events (1.2% vs 0.5%), and 
ophthalmologic events (2.9% vs 1.9%). Major adverse 
cardiovascular events (death from coronary heart disease, 
nonfatal MI, fatal or nonfatal ischemic stroke, or unstable 
angina requiring hospitalization) was lower with 
alirocumab than with placebo (1.7% vs 3.3%; hazard 
ratio, 0.52; P=0.02) (Robinson JG et al, N Engl J Med 
2015; 372:1489-1499).  
 
PEGASUS-TIMI 54: In Patients with >1 Year History 
of MI, Ticagrelor Reduced the Risk of Cardiovascular 
Death, MI, or Stroke and Increased the Risk of Major 
Bleeding  
Over a median of 33 months, among 21,162 patients 
with prior myocardial infarction (MI) randomized to 
ticagrelor 90 mg bid or 60 mg bid, or placebo on top of 
low-dose aspirin, the two ticagrelor doses each reduced, 
as compared with placebo, the rate of the primary 
efficacy end point (cardiovascular death, MI, or stroke) to 
7.85%, 7.77%, and 9.04% respectively (hazard ratios 
0.85, P=0.008 and 0.84; P=0.004 for the two ticagrelor 
doses vs placebo). Rates of TIMI major bleeding were 
higher with ticagrelor (2.6% and 2.3%) than with placebo 
(1.06%) (P<0.001); the rates of intracranial hemorrhage 
or fatal bleeding in the three groups were 0.63%, 0.71%, 
and 0.60%, respectively (Bonaca MP et al, N Engl J Med 
2015; 372:1791-1800). 
 
STAR AF II: Addition of Linear Ablation or Ablation 
of Complex Fractionated Electrograms to Pulmonary 
Vein Isolation did not Reduce Recurrences Among 
Patients with Persistent Atrial Fibrillation (AF)  
Among 589 patients with persistent AF, randomized 
in a 1:4:4 ratio to ablation with pulmonary-vein isolation 
(PVI) alone (n=67), PVI plus ablation of electrograms 
showing complex fractionated activity (n=263), or PVI 
plus additional linear ablation across the left atrial roof 
and mitral valve isthmus (n=259), procedure time was 
shorter for PVI alone (P<0.001). At 1.5 years, 59% of 
patients assigned to PVI alone were free from recurrent 
AF, as compared with 49% assigned to PVI plus complex 
electrogram ablation and 46% assigned to PVI plus linear 
ablation (P=NS). There were no significant differences 
among the 3 groups for freedom from AF after 2 ablation 
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procedures and freedom from any atrial arrhythmia. 
Complications included tamponade (3 patients), stroke or 
transient ischemic attack (3 patients), and atrioesophageal 
fistula (1 patient) (Verma A et al, N Engl J Med 2015; 
372:1812-1822).  
 
THAPCA Trial: In Comatose Children Who Survived 
Out-Of-Hospital Cardiac Arrest, Therapeutic 
Normothermia is Equivalent With Therapeutic 
Hypothermia, Regarding Survival With a Good 
Functional Outcome at 1 Year  
Within 6 hours after return of circulation, 295 
comatose patients (aged 2 days to 18 years) were 
randomly assigned to therapeutic hypothermia (target 
temperature, 33°C) or therapeutic normothermia (target 
temperature, 36.8°C). Analysis of data in 260 patients 
indicated no significant difference in the primary 
outcome (survival at 12 months with good functional 
outcome) between the hypothermia and the normothermia 
group (20% vs 12%; relative likelihood, 1.54; P=0.14). 
The groups had similar incidences of infection and 
serious arrhythmias, use of blood products and 28-day 
mortality (Moler FW et al, N Engl J Med 2015; 372: 
1898-1908).  
 
Swedish Study: Early Cardiopulmonary Resuscitation 
(CPR) (Bystander CPR Before EMS Arrival) in Out-
of-Hospital Cardiac Arrest was Associated with a 30-
Day Survival Rate >2-Fold Higher Than That 
Associated with no CPR Before EMS Arrival 
Analysis of 30,381 witnessed out-of-hospital cardiac 
arrests indicated that CPR was performed before the 
arrival of Emergency Medical Services (EMS) in 15,512 
cases (51.1%) and was not performed before the arrival of 
EMS in 14,869 cases (48.9%). The 30-day survival rate 
was 10.5% when CPR was performed before EMS arrival 
vs 4% when CPR was not performed before EMS arrival 
(P<0.001). Thus, CPR before the arrival of EMS was 
associated with an increased 30-day survival rate (odds 
ratio, 2.15) (Hasselqvist-Ax I et al, N Engl J Med 2015; 
372:2307-2315).  
 
VADT Trial: 10-Year Follow-Up of Patients With 
Type 2 Diabetes Who Had Been Randomized to 
Intensive Glucose Control for 5.6 Years Had 8.6 
Fewer Major Cardiovascular Events per 1000 Person-
Years Than Those Assigned to Standard Therapy, but 
no Improvement in Overall Survival  
The initial VADT had shown that intensive glucose 
lowering, compared with standard therapy, did not reduce 
the rate of major cardiovascular events among 1791 
military veterans at a median of 5.6 years. The difference 
in glycated hemoglobin levels between the 2 groups 
averaged 1.5% points during the trial and declined to 0.2 
to 0.3% points by 3 years after the trial ended. At 
extended follow-up at ~10 years, the intensive-therapy 
group had a significantly lower risk of the primary 
outcome (major cardiovascular event)than did the 
standard-therapy group (hazard ratio, 0.83; P=0.04), with 
an absolute risk reduction of 8.6 major cardiovascular 
events per 1000 person-years, but did not a have reduced 
cardiovascular mortality (hazard ratio, 0.88; P=NS). No 
reduction in total mortality was evident (Hayward RA et 
al, N Engl J Med 2015; 372:2197-2206). 
 
SWIFT PRIME: Stent-Retriever Thrombectomy 
Within 6 Hours, in Addition to i.v. t-PA, Improved 
Functional Outcomes at 90 Days in Stroke Due to 
Occlusions in the Proximal Anterior Intracranial 
Circulation  
 Patients (N=196) with stroke due to occlusions in the 
proximal anterior intracranial circulation, were 
randomized to thrombectomy with use of a stent retriever 
within 6 hours, in addition to intravenous t-PA (n=98), or 
to t-PA alone (n-98). The study was stopped early 
because of efficacy. In the intervention group, the median 
time from qualifying imaging to groin puncture was 57 
min, and the rate of substantial reperfusion at the end of 
the procedure was 88%. Thrombectomy with the stent 
retriever plus i.v. t-PA reduced disability at 90 days 
(P<0.001). The rate of functional independence was 
higher in the intervention group than in the control group 
(60% vs 35%, P<0.001). There were no significant 
between-group differences in 90-day mortality (9% vs 
12%, P=NS) or symptomatic intracranial hemorrhage 
(0% vs 3%, P=NS) (Saver JL et al, N Engl J Med 2015; 
372:2285-2295).  
 
REVASCAT Trial: Anterior Circulation Stroke 
Treated Within 8 Hours After Symptom Onset, With 
Stent Retriever Thrombectomy Had Reduced Severity 
of Post-Stroke Disability and Increased Rate of 
Functional Independence 
Over 2 years, 206 patients who could be treated within 
8 hours after the onset of symptoms of acute ischemic 
stroke and had confirmed proximal anterior circulation 
occlusion and absence of a large infarct on neuroimaging, 
were randomized to receive either medical therapy 
(including i.v. alteplase) and endovascular therapy with 
the Solitaire stent retriever (thrombectomy group) or 
medical therapy alone (control group). Thrombectomy 
reduced the severity of disability and led to higher rates 
of functional independence. At 90 days, the rates of 
intracranial hemorrhage were 1.9% in both groups, and 
rates of death 18.4% and 15.5%, respectively (P=NS) 
(Jovin TG et al, N Engl J Med 2015; 372:2296-2306).  
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IMPROVE-IT: Ezetimibe Added to Statin Therapy 
after Acute Coronary Syndromes Confers 
Incremental Lowering of LDL and Improved 
Cardiovascular Outcomes / Lowering LDL to Levels 
Below Previous Targets Provided Additional Benefit  
A total of 18,144 patients hospitalized for acute 
coronary syndrome within the preceding 10 days and 
having LDL cholesterol levels of 50 - 100 mg/dl (1.3 to 
2.6 mmol/L) if they were receiving lipid-lowering therapy 
or 50 - 125 mg/dl (1.3 to 3.2 mmol/L) if they were not 
receiving lipid-lowering therapy, were randomized to 
combination of simvastatin (40 mg) and ezetimibe (10 
mg) (simvastatin–ezetimibe) or simvastatin (40 mg) and 
placebo (simvastatin monotherapy). Median LDL 
cholesterol level during the study was 53.7 mg/dl (1.4 
mmol/L) in the simvastatin–ezetimibe group, vs 69.5 
mg/dl (1.8 mmol/L) in the simvastatin-monotherapy 
group (P<0.001). The event rate for the primary end point 
(cardiovascular death, nonfatal MI, unstable angina 
requiring rehospitalization, coronary revascularization  
≥30 days after randomization, or nonfatal stroke) at 7 
years was 32.7% in the simvastatin–ezetimibe group vs 
34.7% in the simvastatin-monotherapy group (hazard 
ratio, 0.936; P=0.016). Rates of prespecified muscle, 
gallbladder, and hepatic adverse effects and cancer were 
similar in the two groups (Cannon CP, et al, N Engl J 
Med 2015; 372:2387-2397).  
 
PREPIC 2: In Patients with Severe Acute Pulmonary 
Embolism who Can be Treated with Anticoagulation, 
Use of a Retrievable Inferior Vena Cava Filter is not 
Supported as it did not Reduce the Risk of Recurrent 
Pulmonary Embolism at 3 Months 
Hospitalized patients with acute, symptomatic 
pulmonary embolism associated with leg vein thrombosis 
and at least 1 criterion for severity were assigned to 
retrievable inferior vena cava filter implantation plus 
anticoagulation (filter group; n = 200) or anticoagulation 
alone with no filter implantation (control group; n = 199). 
The filter was successfully inserted in 193 patients and 
was retrieved as planned in 153 of the 164 patients. By 3 
months, recurrent pulmonary embolism had occurred in 6 
patients (3%; all fatal) in the filter group and in 3 patients 
(1.5%; 2 fatal) in the control group (P = NS). Results 
were similar at 6 months. Filter thrombosis occurred in 3 
patients (Mismetti P et al, JAMA 2015; 313:1627-1635).  
 
Fewer than 1 in 10 Eligible Medicare Patients With 
Low Ejection Fraction (EF) Received an ICD Within 1 
Year After MI, Although ICD Implantation was 
Associated With Lower Mortality at 2 Years  
According to an observational study of 10,318 
Medicare beneficiaries with an EF of <35% after MI, the 
cumulative 1-year ICD implantation rate was 8.1% 
(n = 785). Patients with ICD implantation were more 
likely to have prior coronary artery bypass graft 
procedures (31% vs 20%; hazard ratio - HR, 1.49), higher 
peak troponin levels, in-hospital cardiogenic shock (13% 
vs 8%; HR, 1.57), and cardiology follow-up within 2 
weeks after discharge (30% vs 20%; adjusted HR, 1.64) 
relative to patients who did not receive an ICD within 1 
year. Implantation of ICD was associated with lower 2-
year mortality (15.3 events per 100 patient-years / 128 
deaths in 838 patient-years vs 26.4 events per 100 patient-
years / 3033 deaths in 11 479 patient-years; HR, 0.64) 
(Pokorney SD et al, JAMA 2015;313:2433-2440).  
 
Bioprosthetic Mitral Valve Replacement May be a 
Reasonable Alternative to Mechanical Prosthetic 
Valve Replacement in Patients Aged 50 - 69 Years, but 
the 15-Year Follow-Up in this Study is Insufficient to 
Fully Assess Lifetime Risks, Including Reoperation 
Analysis of 3433 patients (aged 50-69 years) who 
underwent mitral valve replacement indicated no survival 
difference between mechanical prosthetic and 
bioprosthetic mitral valves. Actuarial 15-year survival 
was 57.5% after mechanical vs 59.9% after bioprosthetic 
valve replacement (hazard ratio -HR, 0.95, P = NS); the 
15-year cumulative incidence of stroke was higher after 
mechanical valve replacement (65 strokes, 14% vs 41 
strokes; 6.8%; HR, 1.62); reoperation rate was lower for 
mechanical valves (28 reoperations, 5% vs 47 
reoperations, 11.1%; HR, 0.59). The 15-year cumulative 
incidence of a bleeding event was higher for mechanical 
valves (72 events, 14.9% vs 49 events, 9%; HR, 1.50) 
(Chikwe J et al, JAMA 2015; 313:1435-1442).  
 
ENGAGE AF-TIMI 48: Edoxaban Had Greater 
Efficacy than Warfarin in Patients who were VKA 
Naive than VKA Experienced / It Also Significantly 
Reduced Major Bleeding Regardless of Prior VKA 
Exposure 
In a subgroup of the ENGAGE AF-TIMI 48 trial 
which randomized 21,105 patients with atrial fibrillation 
(AF) to edoxaban vs warfarin, over 2.8 years, higher-dose 
edoxaban significantly reduced the risk of stroke or 
systemic embolism in patients who were vitamin K 
antagonist (VKA) naive (hazard ratio - HR 0.71) and was 
similar to warfarin in the VKA experienced. Lower-dose 
edoxaban was similar to warfarin for stroke or systemic 
embolism prevention in VKA naive patients (HR 0.92), 
but was inferior to warfarin in those who were VKA 
experienced (HR 1.31; P = 0.019). Both higher-dose and 
lower-dose edoxaban regimens significantly reduced the 
risk of major bleeding regardless of prior VKA 
experience (P interaction = 0.90 and 0.71, respectively) 
(O'Donoghue ML et al, Eur Heart J 2015; 36: 1470-
1477).  
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MATRIX: In Patients With Acute Coronary 
Syndrome, Radial Compared With Femoral Access 
Reduces Net Adverse Clinical Events, Through a 
Reduction in Major Bleeding and All-Cause Mortality 
 A total of 8404 patients with acute coronary 
syndrome, with or without ST-segment elevation, were 
randomly assigned to radial (4197) or femoral (4207) 
access for coronary angiography and percutaneous 
coronary intervention (PCI). 369 (8.8%) patients with 
radial access had major adverse cardiovascular events, vs 
429 (10.3%) patients with femoral access (rate ratio - RR 
0·85; p=0.0307). 410 (9.8%) patients with radial access 
had net adverse clinical events compared with 486 
(11.7%) patients with femoral access (0.83; p=0.0092). 
The difference was driven by major bleeding (1.6% vs 
2.3%, RR 0.67; p=0.013) and all-cause mortality (1.6% vs 
2.2%, RR 0.72; p=0.045) (Valgimigli M et al, Lancet 
2015; 385 (9986):2465–2476).  
 
PARTNER 1: Similar 5-Year Outcomes of 
Transcatheter and Surgical Aortic Valve Replacement 
for High Surgical Risk Patients With Aortic Stenosis  
The PARTNER trial has shown that mortality at 1, 2, 
and 3 years of transcatheter aortic valve replacement 
(TAVR) is comparable to surgical aortic valve 
replacement (SAVR) for high-risk patients with aortic 
stenosis. The 5-year outcomes were similar. Among 3105 
patients, of whom 699 were enrolled (348 assigned to 
TAVR, 351 assigned to SAVR; mean STS Predicted Risk 
of Mortality score 11.7%), at 5 years, risk of death was 
67.8% in the TAVR group compared with 62.4% in the 
SAVR group (hazard ratio 1.04; p=NS). There was no 
structural valve deterioration requiring surgical valve 
replacement in either group. Moderate or severe aortic 
regurgitation occurred in 40 (14%) of 280 patients in the 
TAVR group and 2 (1%) of 228 in the SAVR group 
(p<0.0001), and was associated with increased 5-year 
mortality in the TAVR group (72.4% for moderate or 
severe aortic regurgitation vs 56.6% for mild aortic 
regurgitation or less; p=0.003). Thus, TAVR as an 
alternative to surgery for patients with high surgical risk 
results in similar clinical outcomes (Mack MJ et al, 
Lancet 2015; 385 (9986): 2477–2484).  
 
5-Year Outcomes of PARTNER 1: Transcatheter 
Aortic Valve Replacement (TAVR) is More Beneficial 
Compared With Standard Treatment For Patients 
With Inoperable Aortic Stenosis  
Of 3015 patients, of whom 358 were enrolled (mean 
age 83 years, STS Predicted Mortality Risk 11.7%, 54% 
female), 179 were assigned to TAVR treatment and 179 
were to standard treatment. 20 patients crossed over from 
the standard treatment group and 10 withdrew from 
study, leaving only 6 patients at 5 years, of whom 5 had 
AVR treatment outside of the study. Mortality at 5 years 
was 71.8% in the TAVR group vs 93.6% in the standard 
treatment group (hazard ratio 0.50; p<0.0001). At 5 years, 
42 (86%) of 49 survivors in the TAVR group had NYHA 
class 1 or 2 symptoms compared with 3 (60%) of 5 in the 
standard treatment group. Echocardiography after TAVR 
showed durable hemodynamic benefit (aortic valve area 
1.52 cm2 and mean gradient 10.6 mmHg at 5 years), with 
no evidence of structural valve deterioration. Thus, 
TAVR is more beneficial than standard treatment for 
treatment of inoperable aortic stenosis (Kapadia SR et al, 
Lancet 2015; 385(9986) 2485–2491).  
 
HYPITAT-II Trial: for Women with Non-Severe 
Hypertensive Disorders at 34–37 Weeks of Gestation, 
Immediate Delivery Might Reduce the Already Small 
Risk of Adverse Maternal Outcomes Compared to 
Expectant Monitoring With Delivery at 37 Weeks, But 
Increases Neonatal Respiratory Distress Syndrome  
Women (N=703) with non-severe hypertensive 
disorders of pregnancy between 34 and 37 weeks of 
gestation were randomly allocated to either induction of 
labour or caesarean section within 24 h (immediate 
delivery, 352) or a strategy aimed at prolonging 
pregnancy until 37 weeks of gestation (expectant 
monitoring, 351). The composite adverse maternal 
outcome (thromboembolic disease, pulmonary edema, 
eclampsia, HELLP syndrome, placental abruption, or 
maternal death), occurred in 4 (1.1%) women having 
immediate delivery vs 11 (3.1%) women allocated to 
expectant monitoring (relative risk - RR 0.36; p=0.069). 
Respiratory distress syndrome was diagnosed in 20 
(5.7%) neonates in the immediate delivery group vs 6 
(1.7%) of 351 neonates in the expectant monitoring group 
(RR 3.3; p=0.005). No maternal or perinatal deaths 
occurred. Thus, routine immediate delivery does not seem 
justified and a strategy of expectant monitoring until the 
clinical situation deteriorates can be considered 
(Broekhuijsen K et al, Lancet 2015;385:2492–2501).  
 
DENERHTN Trial: Optimum and Stepped Care 
Standardized Antihypertensive Treatment (SSAHT) 
With Renal Denervation for Resistant Hypertension 
Decreases Ambulatory Blood Pressure More Than the 
Same SSAHT Alone at 6 Months 
Eligible patients aged 18–75 years received 
indapamide 1.5 mg, ramipril 10 mg (or irbesartan 300 
mg), and amlodipine 10 mg daily for 4 weeks to confirm 
treatment resistance by ambulatory blood pressure 
monitoring. Patients (106 of 1416 screened) were then 
randomly assigned (1:1) to receive either renal 
denervation plus an SSAHT regimen (renal denervation 
group, 53) or the same SSAHT alone (control group, 53). 
For SSAHT, after randomization, spironolactone 25 mg 
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qd, bisoprolol 10 mg qd, prazosin 5 mg qd, and 
rilmenidine 1 mg qd were sequentially added from 
months 2 to 5 in both groups if home blood pressure was 
>135/85 mm Hg. The mean change in daytime 
ambulatory systolic blood pressure at 6 months was 
−15·8 mm Hg in the renal denervation group and −9·9 
mm Hg in the group receiving SSAHT alone, a baseline-
adjusted difference of −5·9 mm Hg (−11·3 to −0·5; 
p=0·0329). The number of antihypertensive drugs and 
drug-adherence at 6 months were similar between the two 
groups. Three minor renal denervation-related adverse 
events were noted (lumbar pain in 2 patients and mild 
groin hematoma in 1 patient). A mild and similar 
decrease in estimated glomerular filtration rate from 
baseline to 6 months was observed in both groups. Thus, 
in patients with well defined resistant hypertension, renal 
denervation plus an SSAHT decreases ambulatory blood 
pressure more than the same SSAHT alone at 6 months 
(Azizi M et al, Lancet 2015; 385(9981):1957–1965).  
 
ROX CONTROL HTN Study: Central Arteriovenous 
(AV) Anastomosis Significantly Reduced Blood 
Pressure and Hypertensive Complications in Patients 
With Uncontrolled Hypertension  
Eligible patients (83 or 43% of 195 screened) with 
baseline office systolic blood pressure of >140 mm Hg 
and average daytime ambulatory blood pressure of 
>135/85 mmHg despite antihypertensive treatment were 
randomly assigned in a 1:1 ratio to undergo implantation 
of an AV coupler device (central iliac AV anastomosis, 
44) plus current drug treatment or to maintain current 
treatment alone (control, 39). Mean office systolic blood 
pressure reduced by 26.9+23.9) mmHg in the AV coupler 
group (p<0.0001) and by 3.7 +21.2 mmHg in the control 
group (p=0.31). Mean systolic 24 h ambulatory blood 
pressure reduced by 13.5+18.8 mmHg (p<0.0001) in AV 
coupler recipients and by 0.5+15.8) mmHg (p=0.86) in 
controls. Late ipsilateral venous stenosis occurred in 12 
(29%) of 42 patients and was treatable with venoplasty or 
stenting. Thus, this approach might be a useful adjunctive 
therapy for patients with uncontrolled hypertension (Lobo 
MD et al, Lancet 2015;385 (9978):1634–1641).  
 
Stanford University Study: Proton Pump Inhibitor 
(PPI) Usage is Associated With Increased Risk of 
Myocardial Infarction in the General Population  
Via a novel “data-mining” approach for pharmaco-
vigilance on multiple electronic medical record datasets 
and a prospectively followed clinical cohort, the 
investigators explored the association of PPIs with 
cardiovascular risk in the general US population (2.9 
million individuals). They found gastroesophageal reflux 
disease (GERD) patients exposed to PPIs to have a 
1.16 fold increased association with myocardial 
infarction (MI). Survival analysis in a prospective cohort 
found a two-fold (HR = 2.00; P = 0.031) increase in 
association with cardiovascular mortality. This 
association was independent of clopidogrel use. 
Contrariwise, H2 blockers were not associated with 
increased cardiovascular risk. The authors concluded 
that their findings support the association of PPI 
exposure with risk for MI in the general population, 
probably by adversely impacting vascular function 
(Shah NH et al, PLoS One 2015;10:e0124653).  
(Editor’s note/N.B.: Some initial criticism indicates that the risk 
of PPIs,  if  real,  is  still  small;  this was not a prospective and a 
formal  epidemiological  study  evaluating  known  risk  factors, 
which would have power to demonstrate a causal relationship; 
patients  with  GERD  may  have  concomitant  multiple  risks  of 
comorbid  diseases; in  addition,  it  cannot  be  determined 
whether  PPIs  were  prescribed  for  chest  pain,  thus  including 
patients  with  coronary  disease.  Most  clinicians  still  believe 
that  the  benefits  of  PPIs  outweigh  their  risks,  but  further 
research  will  be  needed  to  clarify  any  real  association) 
(http://www.jwatch.org/fw110298/2015/06/12/proton-pump-inhibi-
tors-associated-with-increased-mi-risk)/(http://www.gastro.org/ news 
_items/2015/6/11/interpretation-of-study-on-ppi-heart-attack-risk) 
 
Important Review and Other Articles  
Practical management of anticoagulation in AF 
(Kovacs RJ et al, JACC 2015; 65:1340-1360), Manage-
ment of pulmonary hypertension (McLaughlin VV et al, 
JACC 2015;1976-1997), AHA/ACC/ASH Statement on 
treatment of hypertension in patients with coronary artery 
disease (Rosendorff C et al, JACC 2015;65:1998-2038), 
2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus 
Statement on Percutaneous Mechanical Circulatory 
Support Devices (Rihal CS et al, JACC 2015;65:2140-
2141), Bleeding avoidance strategies during PCI (Singh 
M, JACC 2015;65:2225-2238), Functional tricuspid 
regurgitation (Dreyfus GD et al, JACC 2015;65:2331-
2336), Left atrial appendage occlusion (Alli O et al, 
JACC 2015;65:2337-44), Cardio-pulmonary-renal inter-
actions (Husain-Syed F et al, JACC 2015;65:2433-2448), 
Left ventricular assist devices (Mancini D et al, JACC 
2015;65: 2542-2555), PCSK9 inhibitors (Giugliano RP et 
al, JACC 2015;65:2638-51), Percutaneous interventions 
in aortic disease (Aranson NJ et al, Circulation 2015; 
131:1291-1299), Revised Jones criteria for rheumatic 
fever (Gewitz MH et al, Circulation 2015;131: 1806-
1818), Stroke prevention in AF (Lip G & Lane D, JAMA 
2015;313:1950-1962), Stroke prevention (Prabhakaran S 
et al, JAMA 2015; 313:1451-1462 ), Statin associated 
muscle problems (Stroes ES et al, Eur Heart J 2015; 36: 
1012-22), Management of valvular disease in pregnancy 
(Sliwa K et al, Eur Heart J 2015; 36: 1078-1089).  
